Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00500305
Status:
COMPLETED
Last Update Posted:
2018-05-07
First Post:
2007-07-10
Brief Title:
The Use of B-type Natriuretic Peptide BNP to Predict Closure of a Patent Ductus Arteriosus PDA in Premature Infants
Sponsor:
University of Virginia
Organization:
University of Virginia
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A patent ductus arteriosus PDA is associated with increased morbidity in premature infants Standard indomethacin treatment is associated with intestinal and renal morbidity B-type natriuretic peptide is elevated in significant PDAs This study will determine whether BNP guided therapy could reduce doses of indomethacin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None